Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
AGI discontinues lead candidate Rezular for IBS
15 May 2009
Katie McQue

katie.mcque@informa.com

AGI Therapeutics has discontinued its lead product, Rezular (arverapamil), following its failure to meet the primary endpoint of its Phase III study for diarrhoea-predominant irritable bowel syndrome (IBS-D).

The news caused the Dublin-based company's share price to plummet by 64% to €0.17...



Please Login to read the full article.
 
Not a subscriber? Subscribe to Scrip Request a FREE Trial
RELATED CONTENT
NEWS Scrip News Other Informa News
COMMENT Scrip Comment Other Informa Comment
FEATURES Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm